SCHEMBL4667537

SCHEMBL4667537

CN1CCN(CCOc2ccc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccc(F)c(Cl)c5)cc4)ncn3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.41
AXL P30530 1/20 0.41
CXCR1 P25024 1/20 0.40
SRC P12931 2/20 0.40
FGFR1 P11362 1/20 0.40
ABL1 P00519 8/20 0.39
BCR P11274 8/20 0.39
AIMP2 Q13155 1/20 0.38
NTRK1 P04629 1/20 0.38
CYP3A4 P08684 2/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
GLA P06280 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663837 0.94 AXL (0.45) EGFRAXLSRCABL1BCR
SCHEMBL4665825 0.89 ABL1 (0.40) CXCR1SRCFGFR1ABL1BCR
SCHEMBL4664290 0.89 ABL1 (0.43) CXCR1SRCFGFR1ABL1BCR
SCHEMBL4664327 0.88 ABL1 (0.41) SRCFGFR1ABL1BCRAIMP2
SCHEMBL4664335 0.88 ABL1 (0.43) SRCFGFR1ABL1BCRAIMP2
SCHEMBL4665779 0.88 CXCR1 (0.47) CXCR1SRCFGFR1ABL1BCR
SCHEMBL4667432 0.87 CYP3A4 (0.42) CXCR1SRCFGFR1ABL1BCR
SCHEMBL4665727 0.85 GSK3B (0.47) EGFRAXLCXCR1SRCFGFR1
Formic Acid SCHEMBL4667535 0.85 GSK3B (0.44) EGFRAXLCXCR1SRCFGFR1
SCHEMBL4667502 0.85 EGFR (0.36) EGFRAXLABL1BCRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885AXL 223/4885CXCR1 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.